Incyte Corp

26 jun 2026, 23:51 UTC

Incyte Corp shares are higher in after-market trading following a positive recommendation for Opzelura® cream from the European Medicines Agency's Committee for Medicinal Products.

25 jun 2026, 23:51 UTC

Incyte Corp shares are higher in after-market hours, recovering from an earlier session low. Broader market performance remains mixed amid varying tech stock results.

24 jun 2026, 20:02 UTC

HC Wainwright reiterated its Buy rating on Incyte Corp with a $140 price target, contributing to the stock's advance amid positive social media sentiment.

23 jun 2026, 19:46 UTC

Incyte Corp shares are higher today, reflecting a cumulative gain since Monday. The stock has rebounded from an earlier session pullback amid broader market pressures.

22 jun 2026, 20:02 UTC

Incyte Corp's stock is higher after Japan approved Minjuvi for lymphoma treatment. BMO upgraded the company to Market Perform and raised its price target to $94.

18 jun 2026, 22:16 UTC

Incyte Corp shares are trading higher in after-market hours. No specific news was identified to explain this movement amid a broader market uptrend.

17 jun 2026, 23:46 UTC

Incyte Corp shares are lower in after-market trading following significant volatility. Broader market trends may be affecting investor sentiment amid stronger U.S. retail sales.

16 jun 2026, 19:22 UTC

Incyte shares are lower despite positive phase II study results for zilurgisertib. The FDA has begun Priority Review of the New Drug Application.

15 jun 2026, 14:23 UTC

Incyte Corp's stock is lower as analysts raise concerns over clinical data despite promising Phase 3 trial results for tafasitamab.

12 jun 2026, 22:02 UTC

Incyte Corp shares are lower in after-market hours, continuing a trend of unusual weakness since Friday's close, with no specific news identified.

11 jun 2026, 22:02 UTC

Incyte Corp shares are lower in after-market hours, despite being above their 20-day moving average and three consecutive sessions of higher closes.

10 jun 2026, 21:02 UTC

Incyte shares rise in after-market trading on Guggenheim target increase.

9 jun 2026, 20:02 UTC

Incyte Corp gains as HC Wainwright raises price target to $140 and the company announces a $1.25 billion acquisition of Vega Therapeutics.

8 jun 2026, 19:42 UTC

Incyte Corp shares are lower after announcing a $1.25 billion acquisition of Vega Therapeutics, which will impact upcoming financial results significantly.

5 jun 2026, 22:51 UTC

Incyte Corp shares are higher in after-market trading, reflecting positive market sentiment following stronger-than-expected U.S. job growth data.

4 jun 2026, 20:01 UTC

Incyte shares rise as results from the Phase 2 PROGRESS study will be presented at ENDO 2026, supporting the FDA's Priority Review of its application.

3 jun 2026, 20:02 UTC

Incyte Corp shares are higher today, breaking a recent trend. The ADP Employment Report showed stronger-than-expected job growth, influencing broader market sentiment.

2 jun 2026, 23:06 UTC

Incyte Corp. shares are trading roughly flat in after-market hours, following a session that saw a peak gain earlier.

1 jun 2026, 19:36 UTC

Incyte Corp's stock is lower after the Phase 3 frontMIND trial results raised safety concerns despite showing efficacy in treating high-risk lymphoma patients.

29 mei 2026, 23:46 UTC

Incyte Corp shares are lower in after-market hours, reflecting a slight decline since Friday's close without any specific news to explain the movement.

28 mei 2026, 20:06 UTC

Incyte Corp shares are higher today, recovering from earlier losses amid modest overall market performance. No specific company news was identified to explain the movement.

27 mei 2026, 23:06 UTC

Incyte Corp. shares remain roughly flat in after-market trading, with no specific news identified and movement within a narrow range since Wednesday's close.

26 mei 2026, 20:06 UTC

Incyte Corp. shares are lower today, reflecting a decline since Friday's close amid broader market focus on upcoming economic data releases.

21 mei 2026, 19:26 UTC

HC Wainwright & Co. reiterated a Buy rating on Incyte Corp with a $135 price target, contributing to the stock's upward movement since Wednesday.

20 mei 2026, 23:56 UTC

Incyte Corp shares are lower in after-market trading, amid tightening global financial conditions and rising policy rates. The broader market has shown recent strength.

19 mei 2026, 19:36 UTC

Incyte Corp partners with Edison Scientific to use AI in drug discovery. Shares are trading higher, reflecting broader gains in the Biotechnology sector.

18 mei 2026, 19:17 UTC

Incyte Corp shares decline amid rising Treasury yields and broader market pressures. The stock has finished lower for five consecutive sessions.

15 mei 2026, 23:02 UTC

Incyte Corp shares are higher in after-market trading, reversing four consecutive daily declines. No specific news was identified to explain the price movement.

14 mei 2026, 20:06 UTC

Incyte Corp shares are lower today amid a downturn in the Biotechnology sub-sector and a broader market decline over three consecutive sessions.